This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tandospirone
- DrugBank Accession Number
- DB12833
- Background
Tandospirone has been used in trials studying the treatment of Schizophrenia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Tandospirone (DB12833)
- Weight
- Average: 383.496
Monoisotopic: 383.232125194 - Chemical Formula
- C21H29N5O2
- Synonyms
- Tandospirone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Tandospirone. Acenocoumarol The risk or severity of adverse effects can be increased when Tandospirone is combined with Acenocoumarol. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Tandospirone. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Tandospirone. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Tandospirone. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Tandospirone. Alimemazine The risk or severity of CNS depression can be increased when Alimemazine is combined with Tandospirone. Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Tandospirone. Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Tandospirone. Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Tandospirone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Anti-Anxiety Agents
- Antidepressive Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Heterocyclic Compounds, Fused-Ring
- Neurotransmitter Agents
- Psychotropic Drugs
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin Receptor Agonists
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Aromatic monoterpenoids / Isoindolones / Dialkylarylamines / Aminopyrimidines and derivatives / N-alkylpiperazines / Pyrrolidine-2-ones / N-substituted carboxylic acid imides / N-alkylpyrrolidines / Heteroaromatic compounds / Dicarboximides show 8 more
- Substituents
- 2-pyrrolidone / Amine / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Aromatic monoterpenoid / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid imide show 25 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 190230I669
- CAS number
- 87760-53-0
- InChI Key
- CEIJFEGBUDEYSX-FZDBZEDMSA-N
- InChI
- InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
- IUPAC Name
- (1R,2S,6R,7S)-4-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
- SMILES
- [H][C@]12CC[C@]([H])(C1)[C@]1([H])C(=O)N(CCCCN3CCN(CC3)C3=NC=CC=N3)C(=O)[C@]21[H]
References
- General References
- Not Available
- External Links
- PubChem Compound
- 91273
- PubChem Substance
- 347828999
- ChemSpider
- 82421
- BindingDB
- 50099385
- ChEBI
- 145673
- ChEMBL
- CHEMBL274047
- ZINC
- ZINC000001545034
- Wikipedia
- Tandospirone
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Generalized Anxiety Disorder 1 4 Unknown Status Treatment Anxiety / Hypertension 1 4 Unknown Status Treatment Schizophrenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.1 mg/mL ALOGPS logP 1.93 ALOGPS logP 1.5 Chemaxon logS -2.5 ALOGPS pKa (Strongest Basic) 7.62 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 69.64 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 107.11 m3·mol-1 Chemaxon Polarizability 42.98 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 00:35 / Updated at February 21, 2021 18:54